Compare HUDI & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | CLGN |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 18.8M |
| IPO Year | 2021 | N/A |
| Metric | HUDI | CLGN |
|---|---|---|
| Price | $1.16 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 13.5K | ★ 31.5K |
| Earning Date | 01-29-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,566,370.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | $85.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 280.77 |
| 52 Week Low | $1.06 | $1.30 |
| 52 Week High | $5.46 | $4.98 |
| Indicator | HUDI | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 37.22 |
| Support Level | $1.16 | $1.38 |
| Resistance Level | $1.34 | $1.57 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 30.77 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.